Amporin Pharmaceuticals

We are developing a new class of small molecule drugs as the first acute oral disease-modifying treatments for at least 6 deadly chronic degenerative diseases, including Parkinsons disease and ALS.

We have already demonstrated Proof of Concept, with acute oral disease reversal in vivo: A single oral dose of our prototype drug candidate was shown to fully restore cognitive and motor function in two established animal models of Alzheimer’s and Parkinson’s disease, with no adverse effects in normal healthy animals. This has never been seen before.

540 people affected by chronic degenerative diseases globally, with 3.6 million deaths per year, and $3 trillion in global annual healthcare costs, and no effective treatments approved to date. Big Pharma and biotech companies, with a $95 billion current drug market for neurodegenerative diseases, growing by 5% p.a. with the ageing population.

At least 50 deadly chronic degenerative diseases, including Alzheimer’s, Parkinson’s, type II diabetes, and many rare degenerative diseases, are now associated with protein misfolding and aggregation. Together, these diseases affect over half a billion people and kill 3.6 million people around the world each year, at a total cost to society of USD 3 trillion per year. Moreover, these diseases are growing rapidly with the ageing population, and yet there are still no effective treatments that can stop or reverse the underlying process of degeneration.

We are developing 3 breakthrough new classes of small molecule drugs which have been specifically designed to block, dissolve and degrade the toxic soluble oligomers and pores formed by any disease-associated protein or peptide within cell membranes, as the first acute oral disease-modifying treatments for multiple degenerative diseases.

Symptomatic treatments and limited disease-modifying treatments are available, which are only partially effective in delaying progression of disease, with serious side effects such as brain and spinal cord inflammation.

We aim to develop the first fully effective acute oral disease-modifying treatments to stop and reverse disease progression, as an effective cure for multiple chronic degenerative diseases.

Upfront fees, development milestone payments and royalties from licensing of drug candidates to Big Pharma after demonstrating their superior safety and efficacy in early clinical trials.

We plan to develop and license out at least 6 drug candidates to big pharma companies after demonstrating their superior safety and efficacy in Phase 2 trials, or even earlier in Phase 1b trials. Pharma companies are especially desperate to fill their pipelines with potential treatments for these diseases, as shown by several recent multi-billion dollar deals in this space.

- Strengthen scientific data and IP to maximize asset value
- Establish operations (office, lab, team)
- PD: Select lead drug candidate, CMC formulation, begin preclinical testing
- ALS: Lead optimization, in vivo testing and PoC

Exit by trade sale to Big Pharma by 2030
Expect 40-50X exit multiple

Risks are mostly technical and scientific, especially in bioavailability, safety and efficacy, as most drugs for these diseases have failed in development.

Recipient of InnoSuisse initial and core startup coaching grants.

3rd place winner of Swiss Venture business plan competition.
Winner of Venture Kick Stage III support for Swiss Startups.

Patent applications in preparation.